AOT 2026 | Professor Andrew Artz: Current Landscape, Challenges, and Optimization Strategies for Hematopoietic Stem Cell Transplantation in Older Adults in the United States

AOT 2026 | Professor Andrew Artz: Current Landscape, Challenges, and Optimization Strategies for Hematopoietic Stem Cell Transplantation in Older Adults in the United States

To comprehensively improve public health and strengthen strategies for the prevention and treatment of major diseases, medical innovation and international collaboration have become key drivers of clinical progress. Against this backdrop, the 2026 Beijing International Hematopoietic Stem Cell Transplantation Conference (AOT) was successfully held in Beijing from April 24 to 25, 2026. Organized by the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care and hosted by the National Clinical Research Center for Hematologic Diseases and the Peking University Institute of Hematology, this year’s conference centered on the theme “The Art of Transplantation.” The meeting brought together leading hematology experts from around the world to discuss cutting-edge innovations and future trends in hematopoietic stem cell transplantation.
AOT 2026 | Professor Dong-won Baek: Infection Risk and Management Strategies for Patients With GVHD Following Hematopoietic Stem Cell Transplantation

AOT 2026 | Professor Dong-won Baek: Infection Risk and Management Strategies for Patients With GVHD Following Hematopoietic Stem Cell Transplantation

To comprehensively improve public health and strengthen strategies for the prevention and treatment of major diseases, medical innovation and international collaboration have become key drivers of clinical progress. Against this backdrop, the 2026 Beijing International Hematopoietic Stem Cell Transplantation Conference (AOT) was successfully held in Beijing from April 24 to 25, 2026. Organized by the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care and hosted by the National Clinical Research Center for Hematologic Diseases and the Peking University Institute of Hematology, this year’s conference centered on the theme “The Art of Transplantation.” The meeting brought together leading experts in hematology from around the world to discuss cutting-edge innovations and future trends in hematopoietic stem cell transplantation.
AOT 2026 | Professor Hans H. Hirsch: Comprehensive Infection Prevention and Clinical Management for Post-Transplant Reintegration Into the Community

AOT 2026 | Professor Hans H. Hirsch: Comprehensive Infection Prevention and Clinical Management for Post-Transplant Reintegration Into the Community

To comprehensively improve public health and strengthen strategies for the prevention and treatment of major diseases, medical innovation and international collaboration have become key drivers of clinical progress. Against this backdrop, the 2026 Beijing International Hematopoietic Stem Cell Transplantation Conference (AOT) was successfully held in Beijing from April 24 to 25, 2026. Organized by the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care and hosted by the National Clinical Research Center for Hematologic Diseases and the Peking University Institute of Hematology, this year’s conference centered on the theme “The Art of Transplantation.” The meeting brought together leading hematology experts from around the world to discuss cutting-edge innovations and emerging trends in hematopoietic stem cell transplantation.
CSCO BC 10th Anniversary Tribute | President Jinming Yu: A Decade of Growth and Remarkable Achievement — Looking Forward to CSCO BC Continuing to Shape a New Vision for Cancer Prevention and Care While Amplifying China’s Voice

CSCO BC 10th Anniversary Tribute | President Jinming Yu: A Decade of Growth and Remarkable Achievement — Looking Forward to CSCO BC Continuing to Shape a New Vision for Cancer Prevention and Care While Amplifying China’s Voice

As the Breast Cancer Committee of the Chinese Society of Clinical Oncology (CSCO BC) celebrates its 10th anniversary, the 2026 National Breast Cancer Conference was grandly held from April 10–12. More than an academic gathering, this conference served as both a comprehensive review of CSCO BC’s decade-long development and a forward-looking blueprint for the future of breast cancer care in China.
CSCO BC Guidelines & Consensus | Professor Qiang Liu: Interpreting the Chinese Expert Consensus on the Diagnosis and Treatment of Young Breast Cancer (2025 Edition) — Optimizing Risk Stratification and Full-Cycle Management for Young Patients

CSCO BC Guidelines & Consensus | Professor Qiang Liu: Interpreting the Chinese Expert Consensus on the Diagnosis and Treatment of Young Breast Cancer (2025 Edition) — Optimizing Risk Stratification and Full-Cycle Management for Young Patients

The 2026 National Breast Cancer Conference was held in Beijing from April 10–12. During the meeting, Professor Qiang Liu from Sun Yat-sen Memorial Hospital, Sun Yat-sen University delivered a dedicated presentation on the Chinese Expert Consensus on the Diagnosis and Treatment of Young Breast Cancer (2025 Edition).
CSCO BC Guideline Highlights | Professor Man Li: Focusing on HER2-Low and HER2-Ultralow Breast Cancer — Key Updates and Practical Changes in the 2026 Guidelines

CSCO BC Guideline Highlights | Professor Man Li: Focusing on HER2-Low and HER2-Ultralow Breast Cancer — Key Updates and Practical Changes in the 2026 Guidelines

The 2026 National Breast Cancer Conference was successfully held in Beijing from April 10–12, during which the 2026 Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines were officially released. Oncology Frontier invited Professor Man Li from the Second Affiliated Hospital of Dalian Medical University to discuss three key clinical topics surrounding HER2-low and HER2-ultralow breast cancer: major updates in the 2026 guidelines, standardized interpretation of HER2-low/ultralow status, and sequencing strategies for antibody-drug conjugates (ADCs). Her insights provide more precise and practice-oriented guidance for the management of HER2-low and HER2-ultralow breast cancer in China.
CSCO BC Guideline Highlights | Professor Shusen Wang: Key Updates in Advanced Triple-Negative Breast Cancer Management — From Salvage Chemotherapy to a New Era of Immunotherapy-Based Combination Strategies

CSCO BC Guideline Highlights | Professor Shusen Wang: Key Updates in Advanced Triple-Negative Breast Cancer Management — From Salvage Chemotherapy to a New Era of Immunotherapy-Based Combination Strategies

The 2026 National Breast Cancer Conference was held in Beijing from April 10–12, during which the Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2026 (CSCO BC Guidelines 2026) underwent a major update. At the meeting, Professor Shusen Wang from Sun Yat-sen University Cancer Center presented the latest revisions related to the management of advanced triple-negative breast cancer (TNBC).
Nature Communications Publishes Breakthrough Study Led by Academician Xu Binghe and Collaborators: China-Developed AKT Inhibitor Delivers Promising First-in-Human Results

Nature Communications Publishes Breakthrough Study Led by Academician Xu Binghe and Collaborators: China-Developed AKT Inhibitor Delivers Promising First-in-Human Results

On February 6, 2026, Nature Communications published online a study led by Academician Xu Binghe from the National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences. The single-arm Phase Ib trial evaluated the efficacy and safety of the novel oral pan-AKT inhibitor afuresertib combined with fulvestrant in previously treated patients with HR-positive/HER2-negative advanced breast cancer.
A Decade of Pursuing Light, A Future Full of Hope: Tracing the Milestones and Defining Moments of CSCO BC

A Decade of Pursuing Light, A Future Full of Hope: Tracing the Milestones and Defining Moments of CSCO BC

In April 2016, a pink seed took root in Beijing with the launch of preparations for the Breast Cancer Committee of the Chinese Society of Clinical Oncology (CSCO BC). Driven by vision, dedication, and perseverance, a group of Chinese physicians came together to support and empower patients with breast cancer through science, compassion, and unwavering commitment to care.
Sino-French Breast Reconstruction Congress | Professor Hongyuan Li: Building a Bridge for Sino-French Collaboration and Advancing Breast Reconstruction Accessibility and De-escalation Strategies in Oncoplastic Surgery Through the “Chongqing Experience”

Sino-French Breast Reconstruction Congress | Professor Hongyuan Li: Building a Bridge for Sino-French Collaboration and Advancing Breast Reconstruction Accessibility and De-escalation Strategies in Oncoplastic Surgery Through the “Chongqing Experience”

The 15th Sino-French Breast Reconstruction Congress and the 13th Sino-French Breast Cancer Academic Conference recently concluded successfully in Chongqing, China. During the meeting, Oncology Frontier conducted an exclusive interview with Professor Hongyuan Li from the First Affiliated Hospital of Chongqing Medical University (hereafter referred to as CQMU First Hospital), one of the conference’s principal organizers. In the interview, Professor Li shared his insights into the innovative considerations behind this year’s conference design, the reproducible experience of CQMU First Hospital in promoting technical standardization and multidisciplinary talent development, as well as the institution’s “Chongqing Experience” in individualized oncoplastic breast surgery and de-escalation treatment strategies.